Loading…
GH
Guardant Health, Inc.
NASDAQ· Healthcare· Diagnostics & Research· CUSIP 40131M109
$162.94-2.23%Price as of Oct 23, 00:42 UTC · updated once a day, after the close
At a glance
Guardant Health, Inc. (GH) is listed on NASDAQ and classified in Diagnostics & Research, part of the Healthcare sector. It is headquartered in Palo Alto, United States and has 2,490 employees. The company is worth $21.87B. Revenue was $982.02M in fiscal 2025, up 32.9% from the year before. It reported a net loss of $416.28M. The share price is 14.7% below its 52-week high of $191.05. 7 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Two Sigma (Two Sigma Investments), at $558.01M. In that quarter, 3 of them opened or added to the position and 4 reduced it. Over the last 30 days, company insiders sold $30.27K of its stock on the open market and bought none. All of those sales were scheduled in advance under 10b5-1 plans.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Key metrics
- Market cap
- $21.87B
- P/E
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.00%
- Payout
- —
- EPS
- -$3.43
- ROE
- —
- Profit margin
- -38.33%
- Revenue growth
- +44.30%
- Beta
- 1.58
- 52-week high
- $191.05
- 52-week low
- $66.59
History
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Investors holding this
Major managers that reported this stock in their latest 13F.
- Two SigmaReducedTwo Sigma Investments · Q2 2026$558.01M3.72M shares · 0.4% of portfolio
- Baillie GiffordReducedBaillie Gifford & Co · Q2 2026$342.69M2.28M shares · 0.3% of portfolio
- Israel EnglanderAddedMillennium Management · Q2 2026$243.42M1.62M shares · 0.2% of portfolio
Ken GriffinAddedCitadel Advisors · Q2 2026$217.47M1.45M shares · 0.1% of portfolio- Steve CohenAddedPoint72 Asset Management · Q2 2026$138.15M920.81K shares · 0.2% of portfolio
- Cliff AsnessReducedAQR Capital Management · Q2 2026$18.25M121.67K shares · 0.0% of portfolio
Ray DalioReducedBridgewater Associates · Q2 2026$636.73K4.24K shares · 0.0% of portfolio
Price over time
▲ +50.9% over 5Y.
today you would have $1,357.99▲ +35.8%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 8 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $102.14 | $30.55 | $27.05 | $27.20 | $100.02 | $128.88 | $78.14 | $37.59 | |
| P/S | 20.5x | 13.6x | 5.1x | 5.8x | 6.2x | 27.3x | 45.1x | 34.4x | 35.6x |
| P/B | 12.9x | — | — | 20.7x | 46.4x | 15.8x | 10.0x | 9.2x | 6.7x |
| EPS | -$3.32 | -$3.56 | -$4.28 | -$6.41 | -$4.00 | -$2.60 | -$0.84 | -$2.80 | |
| Profit margin | -85.46% | -42.39% | -59.05% | -85.02% | -145.61% | -102.98% | -85.89% | -35.29% | -93.85% |
| ROE | -39.31% | — | — | -302.14% | -1087.72% | -59.65% | -18.97% | -9.48% | -17.61% |
Median of the years shown; P/E years above 200x are left out.
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| THCTenet Healthcare Corp | $270.63 | 10.5x | 4.7x | 0.00% | 37.34% | $21.79B |
| VTRSViatris Inc | $18.48 | — | 1.5x | 2.60% | -2.75% | $21.23B |
| BNTXBioNTech SE | $89.67 | — | 1.1x | 0.00% | -9.30% | $22.53B |
| STESTERIS plc | $232.22 | 27.1x | 3.1x | 1.11% | 11.39% | $22.64B |
| INSMINSMED Inc | $95.06 | — | 27.4x | 0.00% | -87.22% | $20.76B |
| INCYIncyte Corp | $116.93 | 14.5x | 3.7x | 0.00% | 30.67% | $23.7B |
About the company
- 2,490
- Palo Alto, United States